Targeting hirsutism: A new approach

Sexuality, Reproduction and Menopause

Volumn 2, Issue 2, 2004, Pages 101-107

  Kurtis, Boaz ^a   Brenner, Sarah ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; ANDROGEN; CYCLOSPORIN; DIANE; EFLORNITHINE; ESTROGEN; FINASTERIDE; FLUTAMIDE; GESTAGEN; GLUCOCORTICOID; MINOXIDIL; ORAL CONTRACEPTIVE AGENT; ORNITHINE DECARBOXYLASE; PHENOBARBITAL; PHENYTOIN; PLACEBO; SPIRONOLACTONE; STEROID 5ALPHA REDUCTASE;

ACNE; ARTICLE; BURNING SENSATION; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG ABSORPTION; DRUG APPROVAL; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ELECTROLYSIS; ENZYME ACTIVITY; ENZYME INHIBITION; ERYTHEMA; ESTHETIC SURGERY; FEMALE; HAIR GROWTH; HAIR LOSS; HIRSUTISM; HUMAN; HYPERANDROGENISM; IDIOPATHIC DISEASE; INCIDENCE; MEDICAL ASSESSMENT; PARESTHESIA; PATHOPHYSIOLOGY; PHOTOTOXICITY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SYSTEMIC DISEASE; TREATMENT OUTCOME;

EID: 13344278609     PISSN: 15462501     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sram.2004.04.010     Document Type: Review

References (11)

1. Rittmaster RS. Hirsutism. Lancet 1997;349:191-5.
2. Falsetti L, Gambera A, Platto C, Legrenzi L. Management of hirsutism. Am J Clin Dermatol 2000;2: 89-99.
3. Carmina E. Prevalence of idiopathic hirsutism. Eur J Endocrinol 1998;139:421-3.
4. Serafini P, Lobo RA. Increased 5 alpha-reductase activity in idiopathic hirsutism. Fertil Steril 1985; 43:74-8.
5. Fitzpatrick TB, Johnson RA, Wolff K, Suurmond D. Color atlas and synopsis of clinical dermatology. New York, McGraw-Hill, 2001.
6. Coyne PE. The eflornithine story. N Engl J Med 2001;45:784-6.
7. Barman Balfour JA, McClellan K. Topical eflornithine. Am J Clin Dermatol 2001;2:197-201.
8. Bristol-Myers Squibb. Vaniqa patient information leaflet. Buffalo, NY: September 2002.
9. Schrode K, Huber F, Staszak J, et al. Randomized, double-blind, vehicle-controlled safety and efficacy evaluation of eflornithine 15% cream in the treatment of women with excessive facial hair [poster]. American Academy of Dermatology 58th Annual Meeting, March 10-15, 2000, San Francisco, CA.
10. Hickman JG, Huber F, Palmisano M. Human dermal safety studies with eflornithine HCl cream (Vaniqa), a novel treatment for excessive facial hair. Curr Med Res Opin 2001;16:235-44.
11. Bristol-Myers Squibb Company. Women throughout the US are trying Vaniqa® to help manage unwanted facial hair [press release, 2003]. http://www.bms.com/news/press/data/fg_press_release_1388.html.